{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:17:49Z","timestamp":1767892669312,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Isolated locoregional recurrence of breast cancer (ILRR) and contralateral breast cancer (CBC) affect up to 20% of all breast cancer (BC) patients in the first 20\u00a0years after primary diagnosis. Treatment options comprise surgical interventions and further systemic therapies depending on the histological subtype. Patients with hereditary breast or ovarian cancer (HBOC) undergo MRI, mammography, and ultrasound in the aftercare of BC, while non-HBOC (nHBOC) patients do not regularly receive MRI. Since early detection is crucial for morbidity and mortality, the evaluation and constant improvement of imaging methods of the breast is necessary.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively analyzed the data of 1499 former BC patients that received imaging of the breast at a tertiary-care university hospital between 2015 and 2020. The analysis comprised various patient characteristics, such as breast density, age, tumor size and subtype, and their influence on BC detection rates by the different imaging methods.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Within the patient sample, 176 individuals (11.7% of former BC patients) were diagnosed with either ILRR or CBC. CBC was observed in 32.4% of patients, while both ILRR and secondary breast cancer occurred in 20.5% and 23.9% of all patients. Sensitivity of MRI, mammography, and ultrasound for recurrent malignancy was 97.9%, 66.3%, and 67.8%, respectively. ILRR and CBC detection rates were similar for patients with and without HBOC history. Lower breast density and larger tumor size increased the detection rates of all imaging modalities.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In breast cancer survivors, MRI might improve the early detection of ILRR and CBC in both HBOC and nHBOC patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05709-2","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T03:51:01Z","timestamp":1713325861000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Imaging for local recurrence of breast cancer"],"prefix":"10.1007","volume":"150","author":[{"given":"T.","family":"Schlaiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.-L.","family":"Herbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kiesel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Salmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. T.","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. A.","family":"Christner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Petritsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Grunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Woeckel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"L\u00f6b","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Diessner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"5709_CR1","unstructured":"(ACR), American College of Radiology 2019 ACR BI-RADS Atlas Fifth Edition. American College of Radiology (ACR)."},{"issue":"10","key":"5709_CR2","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.ciresp.2020.04.008","volume":"98","author":"M Allue Cabanuz","year":"2020","unstructured":"Allue Cabanuz M et al (2020) Contralateral breast cancer and tumor recurrence in BRCA1\/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy. Cir Esp (engl Ed) 98(10):612\u2013617","journal-title":"Cir Esp (engl Ed)"},{"issue":"1","key":"5709_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10549-019-05152-9","volume":"175","author":"U Bick","year":"2019","unstructured":"Bick U et al (2019) High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer. Breast Cancer Res Treat 175(1):217\u2013228","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"5709_CR4","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/PL00002360","volume":"177","author":"J Dunst","year":"2001","unstructured":"Dunst J et al (2001) Prognostic significance of local recurrence in breast cancer after postmastectomy radiotherapy. Strahlenther Onkol 177(10):504\u2013510","journal-title":"Strahlenther Onkol"},{"issue":"1","key":"5709_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/08465371231184769","volume":"75","author":"A Eisen","year":"2024","unstructured":"Eisen A et al (2024) Breast magnetic resonance imaging for preoperative evaluation of breast cancer: a systematic review and meta-analysis. Can Assoc Radiol J 75(1):118\u2013135","journal-title":"Can Assoc Radiol J"},{"issue":"4","key":"5709_CR6","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/ijc.32396","volume":"146","author":"C Engel","year":"2020","unstructured":"Engel C et al (2020) Breast cancer risk in BRCA1\/2 mutation carriers and noncarriers under prospective intensified surveillance. Int J Cancer 146(4):999\u20131009","journal-title":"Int J Cancer"},{"issue":"10","key":"5709_CR7","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1245\/s10434-014-3906-0","volume":"21","author":"D Euhus","year":"2014","unstructured":"Euhus D (2014) Genetic testing today. Ann Surg Oncol 21(10):3209\u20133215","journal-title":"Ann Surg Oncol"},{"key":"5709_CR8","unstructured":"G-BA 2001 Magnetresonanz-Tomographie der weiblichen Brust (MRM)."},{"issue":"12","key":"5709_CR9","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1245\/s10434-012-2404-5","volume":"19","author":"O Gentilini","year":"2012","unstructured":"Gentilini O et al (2012) Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates. Ann Surg Oncol 19(12):3771\u20133776","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"5709_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L et al (2016) 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17(6):791\u2013800","journal-title":"Lancet Oncol"},{"key":"5709_CR11","unstructured":"Gluz\/Heil 2022 Lokoregion\u00e4res Rezidiv: Arbeitsgruppe Onkologie (AGO) Mamma."},{"issue":"2","key":"5709_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0360-3016(91)90774-X","volume":"21","author":"BG Haffty","year":"1991","unstructured":"Haffty BG et al (1991) Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 21(2):293\u2013298","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"23","key":"5709_CR13","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB et al (2017) Risks of breast, ovarian, and contralateral breast cancer for brca1 and brca2 mutation carriers. JAMA 317(23):2402\u20132416","journal-title":"JAMA"},{"issue":"6","key":"5709_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252476","volume":"16","author":"J Lee","year":"2021","unstructured":"Lee J, Kang BJ, Kim SH (2021) Usefulness of postoperative surveillance MR for women after breast-conservation therapy: focusing on MR features of early and late recurrent breast cancer. PLoS ONE 16(6):e0252476","journal-title":"PLoS ONE"},{"issue":"1","key":"5709_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13058-016-0778-1","volume":"18","author":"S Malkov","year":"2016","unstructured":"Malkov S et al (2016) Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status. Breast Cancer Res 18(1):122","journal-title":"Breast Cancer Res"},{"issue":"22","key":"5709_CR16","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147\u20132159","journal-title":"N Engl J Med"},{"issue":"19","key":"5709_CR17","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H et al (2017) 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836\u20131846","journal-title":"N Engl J Med"},{"issue":"6","key":"5709_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P et al (2022) Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 386(6):556\u2013567","journal-title":"N Engl J Med"},{"issue":"6","key":"5709_CR19","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/pon.5379","volume":"29","author":"A Srethbhakdi","year":"2020","unstructured":"Srethbhakdi A et al (2020) Contralateral prophylactic mastectomy for unilateral breast cancer in women at average risk: systematic review of patient reported outcomes. Psychooncology 29(6):960\u2013973","journal-title":"Psychooncology"},{"issue":"4","key":"5709_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1159\/000331339","volume":"6","author":"JD Strehl","year":"2011","unstructured":"Strehl JD et al (2011) Invasive breast cancer: recognition of molecular subtypes. Breast Care (basel) 6(4):258\u2013264","journal-title":"Breast Care (basel)"},{"issue":"25","key":"5709_CR21","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384(25):2394\u20132405","journal-title":"N Engl J Med"},{"issue":"3","key":"5709_CR22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/sj.bjc.6602703","volume":"93","author":"TC van Sprundel","year":"2005","unstructured":"van Sprundel TC et al (2005) Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 93(3):287\u2013292","journal-title":"Br J Cancer"},{"issue":"7","key":"5709_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G et al (2019) Trastuzumab emtansine for residual invasive her2-positive breast cancer. N Engl J Med 380(7):617\u2013628","journal-title":"N Engl J Med"},{"issue":"13","key":"5709_CR24","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2005.04.3273","volume":"24","author":"IL Wapnir","year":"2006","unstructured":"Wapnir IL et al (2006) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five national surgical adjuvant breast and bowel project node-positive adjuvant breast cancer trials. J Clin Oncol 24(13):2028\u20132037","journal-title":"J Clin Oncol"},{"issue":"11","key":"5709_CR25","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1200\/JCO.2017.76.5719","volume":"36","author":"IL Wapnir","year":"2018","unstructured":"Wapnir IL et al (2018) Efficacy of chemotherapy for er-negative and er-positive isolated locoregional recurrence of breast cancer: final analysis of the calor trial. J Clin Oncol 36(11):1073\u20131079","journal-title":"J Clin Oncol"},{"key":"5709_CR26","unstructured":"W\u00f6ckel, A.; Heuschmann, P.U. 2024 BETTER CARE- BrEasT cancer afTERCARE follow up and programm."},{"issue":"6","key":"5709_CR27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/jcm7060133","volume":"7","author":"Z Xiong","year":"2018","unstructured":"Xiong Z et al (2018) Patterns of occurrence and outcomes of contralateral breast cancer: analysis of SEER data. J Clin Med 7(6):133","journal-title":"J Clin Med"},{"issue":"35","key":"5709_CR28","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.21.00640","volume":"39","author":"S Yadav","year":"2021","unstructured":"Yadav S et al (2021) Germline pathogenic variants in cancer predisposition genes among women with invasive lobular carcinoma of the breast. J Clin Oncol 39(35):3918\u20133926","journal-title":"J Clin Oncol"},{"issue":"1","key":"5709_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12880-018-0303-3","volume":"19","author":"YK Yeom","year":"2019","unstructured":"Yeom YK et al (2019) Screening mammography for second breast cancers in women with history of early-stage breast cancer: factors and causes associated with non-detection. BMC Med Imaging 19(1):2","journal-title":"BMC Med Imaging"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05709-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05709-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05709-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T04:09:20Z","timestamp":1716437360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05709-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,17]]},"references-count":29,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["5709"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05709-2","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,17]]},"assertion":[{"value":"12 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was unnecessary due to the retrospective design of the study (reference number 2163183).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The need for additional written informed consent was waived by the local ethics committee (reference number 2163183).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"200"}}